Therapeutic targets in melanoma: MAPKinase pathway

Current Oncology Reports

Volumn 8, Issue 5, 2006, Pages 400-405

  Haluska, Frank G ^a   Ibrahim, Nageatte ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; AZD 6244; B RAF KINASE; BEVACIZUMAB; CARBOPLATIN; CHIR 265; LONAFARNIB; MAMMALIAN TARGET OF RAPAMYCIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; ONCOPROTEIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PROTEIN P16; PROTEIN P16INK4A; PROTEIN P53; RAS PROTEIN; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CARCINOGENESIS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG TARGETING; GENE LOSS; GENE MUTATION; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; HUMAN; MALIGNANT TRANSFORMATION; MELANOCYTE; MELANOMA; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SOMATIC CELL GENETICS; UPREGULATION;

DRUG THERAPY, COMBINATION; HUMANS; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; SKIN NEOPLASMS;

EID: 33748348982     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-006-0065-x     Document Type: Review

References (41)

1. Talpaz M, Shah NP, Kantarjian H, et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531-2541.
2. Demetri GD: Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development. Hematol Oncol Clin North Am 2002, 16:1115-1124.
3. Haluska FG, Tsao H, Wu H, et al.: Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 2006, 12:2301s-2307s.
4. Baccarini M: An old kinase on a new path: Raf and apoptosis. Cell Death Differ 2002, 9:783-785.
5. Davies H, Bignell GR, Cox C, et al.: Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
6. Pollock PM, Harper UL, Hansen KS, et al.: High frequency of BRAF mutations in nevi. Nat Genet 2003, 33:19-20.
7. Michaloglou C, Vredeveld LC, Soengas MS, et al.: BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436:720-724.
8. Tsao H, Zhang X, Fowlkes K, Haluska FG: Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 2000, 60:1800-1804.
9. Chin L, Pomerantz J, Polsky D, et al.: Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 1997, 11:2822-2834.
10. Tsao H, Zhang X, Benoit E, Haluska FG: Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 1998, 16:3397-3402.
11. Tsao H, Goel V, Wu H, et al.: Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004, 122:337-341.
12. Goel VK, Lazar AJ, Warneke CL, et al.: Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol 2006, 126:154-160.
13. Curtin JA, Fridlyand J, Kageshita T, et al.: Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353:2135-2147.
14. Lang J, MacKie RM: Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. J Invest Dermatol 2005, 125:575-579.
15. Sensi M, Nicolini G, Petti C, et al.: Mutually exclusive NRAS(Q61R) and BRAF(V600E) mutations at the single-cell level in the same human melanoma. Oncogene 2006, 25:3357-3364.
16. Chin L, Tam A, Pomerantz J, et al.: Essential role for oncogenic Ras in tumour maintenance. Nature 1999, 400:468-472.
17. Eskandarpour M, Kiaii S, Zhu C, et al.: Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. Int J Cancer 2005, 115:65-73.
18. Hoeflich KP, Gray DC, Eby MT, et al.: Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 2006, 66:999-1006.
19. Lynch TJ, Bell DW, Sordella R, et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
20. Yeh AH, Bohula EA, Macaulay VM: Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs. Oncogene 2006 May 22; [Epub ahead of print].
21. McGill GG, Haq R, Nishimura EK, Fisher DE: c-Met expression is regulated by Mitf in the melanocyte lineage. J Biol Chem 2006, 281:10365-10373.
22. Garraway LA, Widlund HR, Rubin MA, et al.: Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005, 436:117-122.
23. Solit DB, Garraway LA, Pratilas CA, et al.: BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
24. Ozen M, Medrano EE, Ittmann M: Inhibition of proliferation and survival of melanoma cells by adenoviral-mediated expression of dominant negative fibroblast growth factor receptor. Melanoma Res 2004, 14:13-21.
25. Willmore-Payne C, Holden JA, Hirschowitz J, Layfield LJ: BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Hum Pathol 2006, 37:520-527.
26. Chun KH, Lee HY, Hassan K, et al.: Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells. Cancer Res 2003, 63:4796-4800.
27. Strumberg D, Richly H, Hilger RA, et al.: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005, 23:965-972.
28. Awada A, Hendlisz A, Gil T, et al.: Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005, 92:1855-1861.
29. Flaherty KT: Chemotherapy and targeted therapy combinations in advanced melanoma. Clin Cancer Res 2006, 12:2366s-2370s.
30. Flaherty KT, Lee RJ, Humphries R, O'Dwyer PJ, Schiller J: Phase I trial of BAY 43-9006 in combination with carboplatin (C) and paclitaxel (P) [abstract]. Proc ASCO 2003, 22:710.
31. Amaravadi RK, Shcuchter LM, Kramer A, et al.: Preliminary results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. J Clin Oncol 2006, 24:8009.
32. Escudier B, Szczylik C, Eisen T, et al.: Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2005, 23:4510.
33. Sebolt-Leopold JS, Herrera R: Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004, 4:937-947.
34. Rinehart J, Adjei AA, Lorusso PM, et al.: Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004, 22:4456-4462.
35. Thompson N, Lyons J: Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 2005, 5:350-356.
36. Peralba JM, DeGraffenried L, Friedrichs W, et al.: Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 2003, 9:2887-2892.
37. Garber K: Synthetic lethality: killing cancer with cancer. J Natl Cancer Inst 2002, 94:1666-1668.
38. Grunwald V, DeGraffenried L, Russel D, et al.: Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002, 62:6141-6145.
39. Shi Y, Gera J, Hu L, et al.: Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 2002, 62:5027-5034.
40. Hudes GR, Carducci M, Tomczak P, et al.: A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment fo first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol 2006, 24:LBA4.
41. Margolin K, Longmate J, Baratta T, et al.: CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 2005, 104:1045-1048.